Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + mGEMOX in Advanced Biliary Tract Cancer (BREGO)
NCT02386397Phase 2Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Sep 2014
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in biliary tract cancer (BTC), sponsored by Institut du Cancer de Montpellier. Started Sep 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02386397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386397.